Abstract
Background:
It is well known that selective serotonin reuptake inhibitors (SSRIs) can cause sexual dysfunction, so it is possible that sibutramine, a serotonin and norepinephrine reuptake inhibitor, could induce sexual dysfunction.
Design and subjects:
The effect of sibutramine on sexual function was evaluated in 46 overweight and obese (body mass index (BMI) ⩾23 kg/m2) but otherwise healthy married women (28–44 years). Participants were randomly assigned at baseline to either the sibutramine or control group. The Female Sexual Function Index (FSFI) questionnaire was used to assess sexual function at baseline and after treatment with behavioral therapy plus sibutramine 10 mg once daily or behavioral therapy alone (control) for 8 weeks.
Results:
Mean weight loss from baseline to week 8 was −6.03% in sibutramine group and −0.38% in the control group. There was significant improvement of FSFI total score, arousal domain score and lubrication domain score in the sibutramine group (P<0.05), and significant differences in arousal, orgasm, satisfaction domain score and total score (P<0.05) in favor of sibutramine. Decreases in body weight and BMI were correlated with the improvement of arousal (r=−0.44 and r=−0.48, respectively) and orgasm (r=−0.45 and r=−0.46, respectively) domains.
Conclusion:
Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women. The degree of improvement in sexual function was correlated with the degree of weight reduction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American Psychiatric Association: Washington, DC, 1994.
Brassil DF, Keller M . Female sexual dysfunction: definitions, causes, and treatment. Urol Nurs 2002; 22: 237–244, 284; quiz 245, 248.
Berman JR, Bassuk J . Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002; 20: 111–118.
Ashton AK, Hamer R, Rosen RC . Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 1997; 23: 165–175.
Rosen RC, Lane RM, Menza M . Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67–85.
Goldstein DJ, Rampey Jr AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR . Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129–135.
National Heart, Lung, and Blood Institute Obesity Education Initiative. The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute: Rockville, MD, October 2000. NIH Publication Number 00-4084.
Finer N . Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4): S29–S33.
Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC . Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998; 22 (Suppl 1): S18–S28.
WHO Global Strategy on Diet Physical Activity and Health: South-East Asia Regional Consultation Meeting Report, New Delhi, India, 10–12 March 2003.
WHO Regional Office for the Western Pacific/International Association for the Study of Obesity/International Obesity Task Force. The Asia–Pacific Perspective: Redefining Obesity and Its Treatment. Health Communications Australia: Sydney, 2000.
Brownell KD . The LEARN Program for Weight Management, 10th edn. American Health Publishing Co: Dallas, Texas, 2004.
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191–208.
Meston CM, Frohlich PF . Update on female sexual function. Curr Opin Urol 2001; 11: 603–609.
Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888–893.
Taylor AE . Polycystic ovary syndrome. Endocrinol Metab Clin N Am 1998; 27: 877–902.
Adolfsson B, Elofsson S, Rossner S, Unden AL . Are sexual dissatisfaction and sexual abuse associated with obesity? A population-based study. Obes Res 2004; 12: 1702–1709.
Arenton LW . Factors in the sexual satisfaction of obese women in relationships. Electron J Hum Sexuality 5, Available at: http://www.ejhs.org/volume5/Areton/TOC.htm. Accessed August 16, 2005.
Kolotkin RL, Head S, Hamilton M, Tse CK . Assessing impact of weight on quality of life. Obes Res 1995; 3: 49–56.
Werlinger K, King TK, Clark MM, Pera V, Wincze JP . Perceived changes in sexual functioning and body image following weight loss in an obese female population: a pilot study. J Sex Marital Ther 1997; 23: 74–78.
Rand CS, Kuldau JM, Robbins L . Surgerry for obesity and marriage quality. JAMA 1982; 247: 1419–1422.
Turcato E, Zamboni M, De Pergola G, Armellini F, Zivelonghi A, Bergamo-Andreis IA et al. Interrelationships between weight loss, body fat distribution and sex hormones in pre- and postmenopausal obese women. J Intern Med 1997; 241: 363–372.
Dixon JB, O'Brien PE . Neck circumference a good predictor of raised insulin and free androgen index in obese premenopausal women: changes with weight loss. Clin Endocrinol 2002; 57: 769–778.
Hainer V, Kunesova M, Stunkard AJ, Parizkova J, Stich V, Mikulova R et al. The within-pair resemblance in serum levels of androgens, sex-hormone binding globulin and cortisol in female obese identical twins – effect of negative energy balance induced by very low-calorie diet. Horm Metab Res 2001; 33: 417–422.
Jakubowicz DJ, Nestler JE . 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556–560.
Shifren JL . The role of androgens in female sexual dysfunction. Mayo Clin Proc 2004; 79 (Suppl 4): S19–S24.
Sherwin BB, Gelfand MM, Brender W . Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47: 339–351.
Davis S, McCloud P, Strauss B, Burger H . Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1996; 21: 227–236.
Stunkard AJ, Stinnett JL, Smoller JW . Psychological and social aspects of the surgical treatment of obesity. Am J Psychiatry 1986; 143: 417–429.
Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189–198.
Smith IG, Goulder MA . Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505–512.
Wadden TA, Foster GD, Wang J, Pierson RN, Yang MU, Moreland K et al. Clinical correlates of short- and long-term weight loss. Am J Clin Nutr 1992; 56 (Suppl 1): S271–S274.
James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119–2125.
Krejs GJ . Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4): S34–S37.
Sabuncu T, Ucar E, Birden F, Yasar O . The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab 2004; 17: 103–107.
Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682–688.
Baldwin DS . Depression and sexual dysfunction. Br Med Bull 2001; 57: 81–99.
Clayton AH, McGarvey EL, Clavet GJ, Piazza L . Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997; 33: 747–753.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, K., Kang, H., Kim, S. et al. Influence of weight reduction by sibutramine on female sexual function. Int J Obes 30, 758–763 (2006). https://doi.org/10.1038/sj.ijo.0803198
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0803198
Keywords
This article is cited by
-
Impact of Bariatric Surgery on Female Sexual Function in Obese Patients: a Meta-Analysis
Obesity Surgery (2020)
-
Sexual Functioning and Obesity: A Review
Obesity (2012)
-
Improvements in sexual quality of life after moderate weight loss
International Journal of Impotence Research (2008)